| 1 | 32222463 | Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. | Life Sci | 2020 Jul 15 |
2 |
| 2 | 32277040 | Structure of the RNA-dependent RNA polymerase from COVID-19 virus. | Science | 2020 May 15 |
1 |
| 3 | 32283108 | Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. | Antiviral Res | 2020 Jun |
2 |
| 4 | 32284326 | Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. | J Biol Chem | 2020 May 15 |
6 |
| 5 | 32338164 | SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an <i>in silico</i> perspective. | J Biomol Struct Dyn | 2021 Jun |
1 |
| 6 | 32358203 | Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. | Science | 2020 Jun 26 |
3 |
| 7 | 32375574 | Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. | J Biomol Struct Dyn | 2021 Jul |
1 |
| 8 | 32422376 | Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report. | Int J Infect Dis | 2020 Aug |
1 |
| 9 | 32492200 | Remdesivir and tocilizumab: Mix or match. | J Med Virol | 2021 Jan |
1 |
| 10 | 32511290 | Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins. | ChemRxiv | 2020 Apr 8 |
1 |
| 11 | 32517353 | Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. | J Clin Med | 2020 Jun 7 |
1 |
| 12 | 32521159 | Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase. | J Phys Chem B | 2020 Aug 13 |
7 |
| 13 | 32550880 | Recommandations EMA sur l’usage compassionnel du remdesivir. | Rev Francoph Lab | 2020 Jun |
1 |
| 14 | 32563812 | A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. | Eur J Med Chem | 2020 Sep 1 |
1 |
| 15 | 32568620 | Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - <i>in silico</i> approach. | J Biomol Struct Dyn | 2021 Aug |
1 |
| 16 | 32573468 | Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. | Clin Chem Lab Med | 2020 Aug 27 |
1 |
| 17 | 32594120 | Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. | Clin Infect Dis | 2021 Apr 8 |
3 |
| 18 | 32607511 | A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. | bioRxiv | 2020 Jun 23 |
1 |
| 19 | 32643603 | Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. | Cell | 2020 Aug 6 |
2 |
| 20 | 32686993 | Network analysis, sequence and structure dynamics of key proteins of coronavirus and human host, and molecular docking of selected phytochemicals of nine medicinal plants. | J Biomol Struct Dyn | 2021 Oct |
4 |
| 21 | 32702590 | Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation. | J Mol Graph Model | 2020 Nov |
1 |
| 22 | 32729392 | Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19. | J Biomol Struct Dyn | 2021 Oct |
2 |
| 23 | 32753375 | BET 1: The role of remdesivir in COVID-19 infection. | Emerg Med J | 2020 Aug |
1 |
| 24 | 32754599 | nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. | Front Cell Dev Biol | 2020 |
1 |
| 25 | 32793908 | Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells. | bioRxiv | 2020 Sep 2 |
9 |
| 26 | 32834722 | ICER update to pricing models of remdesivir for COVID-19. | PharmacoEcon Outcomes News | 2020 |
1 |
| 27 | 32836709 | Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach. | Med J Armed Forces India | 2021 Jul |
1 |
| 28 | 32869031 | Elucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR-Cas9 screening and transcriptomics. | bioRxiv | 2020 Aug 28 |
3 |
| 29 | 32887884 | Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. | Nat Commun | 2020 Sep 4 |
1 |
| 30 | 32904625 | Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (M<sup>pro</sup>): A computational study. | J Mol Struct | 2021 Jan 15 |
1 |
| 31 | 32943188 | RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. | Biochem Biophys Res Commun | 2021 Jan 29 |
3 |
| 32 | 32947136 | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. | Bioorg Chem | 2020 Nov |
1 |
| 33 | 32967965 | Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. | J Biol Chem | 2020 Nov 20 |
3 |
| 34 | 33012543 | Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients. | Transplant Proc | 2020 Nov |
1 |
| 35 | 33100032 | Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV. | SAR QSAR Environ Res | 2020 Nov |
9 |
| 36 | 33102688 | <i>In silico</i> identification of drug candidates against COVID-19. | Inform Med Unlocked | 2020 |
1 |
| 37 | 33151166 | Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies. | Acta Pharm | 2021 Jun 1 |
1 |
| 38 | 33176643 | Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19. | Curr Pharm Biotechnol | 2021 |
1 |
| 39 | 33179852 | Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. | EMBO Mol Med | 2021 Jan 11 |
2 |
| 40 | 33183178 | Identification of natural inhibitors against prime targets of SARS-CoV-2 using molecular docking, molecular dynamics simulation and MM-PBSA approaches. | J Biomol Struct Dyn | 2022 Apr |
3 |
| 41 | 33185784 | Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. | Protein J | 2020 Dec |
2 |
| 42 | 33190493 | Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study. | J Phys Chem B | 2020 Nov 25 |
3 |
| 43 | 33237691 | Lipid and Lipoprotein Levels in Patients with COVID-19 Infections | | 2000 |
1 |
| 44 | 33245731 | MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. | Oncotarget | 2020 Nov 17 |
13 |
| 45 | 33260103 | Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2. | Comput Biol Med | 2021 Feb |
6 |
| 46 | 33261845 | Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. | Bioorg Chem | 2021 Jan |
1 |
| 47 | 33262564 | ICER's second update to pricing models of remdesivir for COVID-19. | PharmacoEcon Outcomes News | 2020 |
1 |
| 48 | 33264025 | Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations. | J Phys Chem B | 2020 Dec 17 |
10 |
| 49 | 33281478 | The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp. | Saudi J Biol Sci | 2021 Feb |
2 |
| 50 | 33283177 | Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase. | iScience | 2020 Dec 18 |
1 |